Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
07/2005
07/14/2005WO2005063737A1 Amidopyrazole derivative
07/14/2005WO2005063736A1 Aminoalkylpyrazole derivative
07/14/2005WO2005063725A1 Phenylpropanoic acid derivatives
07/14/2005WO2005063722A1 Stereoisomers and stereoisomeric mixtures of 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamide synthetic intermediates
07/14/2005WO2005063720A1 Amide derivative and medicine
07/14/2005WO2005063716A1 Imidazoles and their use cck-1 receptor modulators
07/14/2005WO2005063715A1 Polymorph of birb 796, a p38map kinase inhibitor
07/14/2005WO2005063712A1 5-ht2 receptors modulators, their pharmaceuticals compositions and their use for the treatment of cardiovascular and muscle diseases
07/14/2005WO2005063711A1 Crystal form of quinoline compound and process for its production
07/14/2005WO2005063705A1 Benzene compounds disubstituted with cyclic groups at the 1- and 2-positions
07/14/2005WO2005063704A1 Azetidine ring compounds and drugs comprising the same
07/14/2005WO2005063702A1 Preparation of r-5-(2-(2-ethoxyphenoxyetylamino)propyl)-2- methoxybenzenesulphonamide hydrochloride of high chemical
07/14/2005WO2005063701A1 Synthesis of optically pure (r)-5-(2-aminopropyl)-2-methoxybenzenesulphonamide
07/14/2005WO2005063697A2 Substituted n-aryl amidines as selective d1 dopamine receptor antagonists for the treatment of obesity and cns disorders
07/14/2005WO2005063665A1 Propofol analogs, process for their preparation, and methods of use
07/14/2005WO2005063318A1 Stent with therapeutically active drug coated thereon
07/14/2005WO2005063300A2 Cosmetic or pharmaceutical preparations containing nucleic acid sequences forming a superstructure
07/14/2005WO2005063297A2 Melatonin combination therapy for improving sleep quality
07/14/2005WO2005063296A2 Therapeutic combination for cognition enhancement and psychotic disorders
07/14/2005WO2005063295A1 Agents for treatment of glaucomatous retinopathy and optic neuropathy
07/14/2005WO2005063294A1 Inhibitor for the formation of ϝ-secretase complex
07/14/2005WO2005063293A1 Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient
07/14/2005WO2005063281A2 Means for inhibiting viral replication by regulation of protein folding
07/14/2005WO2005063277A1 18-membered nitrobenzyl-substituted and aminobenzyl-substituted cyclohexadepsipeptides for controlling endoparasites, and method for the production thereof
07/14/2005WO2005063276A1 Methods and compositions using gonadotropin hormone releasing hormone
07/14/2005WO2005063275A1 Methods and compositions for the prevention and treatment of inflammatory diseases or conditions
07/14/2005WO2005063273A1 Composition comprising xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof
07/14/2005WO2005063270A1 Composition comprising an aqueous extract of red vine leaves and a diuretic for the treatment of chronic venous insufficiences
07/14/2005WO2005063269A1 Composition comprising an aqueous extract of red vine leaves and a antithrombotic agent for the treatment of chronic venous insufficiences
07/14/2005WO2005063268A1 Composition comprising an aqueous extract of red vine leaves and a blood circulation-improving agent for the treatment of chronic venous insufficiences
07/14/2005WO2005063266A1 Therapeutical composition for the treatment of dermatosis comprising an extract of calendula officinalis and hypericum perforatum
07/14/2005WO2005063264A1 Immunopotentiator and method of enhancing immunological activity with the same
07/14/2005WO2005063263A1 Novel derivatives of morphine-6-glucuronide, pharmaceutical compositions containing said derivatives, preparation method thereof and uses of same
07/14/2005WO2005063262A1 Use of p-benzaldehyde-o-beta-d-allopyranoside in treating neuropathic pain
07/14/2005WO2005063261A1 Aminoglycoside antibiotics for use as vap-1/ssao inhibitors
07/14/2005WO2005063260A2 Methods and compositions for the prevention of toxic side effects of aminoglycoside medications
07/14/2005WO2005063259A1 Compounds for the inhibition of undesired cell proliferation and use thereof
07/14/2005WO2005063258A1 Kinase inhibitor phosphonate conjugates
07/14/2005WO2005063257A1 Florfenicol prodrug having improved water solubility
07/14/2005WO2005063256A2 Coating method
07/14/2005WO2005063255A1 Pharmaceutical composition for treating and preventing cancer comprising cinnamoni cortex extract and zizyphi fructus extract
07/14/2005WO2005063254A2 Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
07/14/2005WO2005063253A1 Medicinal composition for treating allergic symptoms
07/14/2005WO2005063252A1 Cdk2 antagonists as short form c-maf transcription factor antagonists for treatment of glaucoma
07/14/2005WO2005063251A1 Modified stent useful for delivery of drugs along stent strut
07/14/2005WO2005063250A1 Neutrophilia inhibitor
07/14/2005WO2005063249A1 Agents for treatment of diabetic retinopathy and drusen formation in macular degeneration
07/14/2005WO2005063248A1 Modafinil combination therapy for improving sleep quality
07/14/2005WO2005063247A1 Aryl sulfonamide compounds and uses related thereto
07/14/2005WO2005063246A1 Method for treatment of multiple sclerosis
07/14/2005WO2005063245A1 Composition for lowering blood pressure
07/14/2005WO2005063244A1 Acidic quinoline derivatives and their use for the prevention and/or treatment of hyperglycaemia-related pathologies
07/14/2005WO2005063243A1 Pharmaceutical compositions
07/14/2005WO2005063242A1 Use of macrolides for treating or preventing airflow obstruction
07/14/2005WO2005063241A1 Preventive and/or therapeutic agent for disease in which mitochondrial benzodiazepine receptor participates
07/14/2005WO2005063240A1 Methods and compositions for treatment of hypertension
07/14/2005WO2005063239A1 3-(4-piperidine-1ylmethyl-phenyl)-propion acid-phenylamide-derivatives and related compounds used in the form of mch antagonists (melanine concentrating hormone) for treating eating disorders
07/14/2005WO2005063238A1 Use of substituted 2-aminotetralines for the preventative treatment of parkinson's disease
07/14/2005WO2005063237A1 Use of rotigotine for the treatment or prevention of dopaminergic neurone loss
07/14/2005WO2005063236A1 Intranasal formulation of rotigotine
07/14/2005WO2005063235A1 Anticancer therapy-aiding composition comprising polyphenol, and ascorbic acid or the derivatives
07/14/2005WO2005063234A2 Use of at least one effector of glutathione metabolism, together with alpha-liponic acid for the treatment of lung diseases
07/14/2005WO2005063233A1 Composition for preventing and treating hepatoma
07/14/2005WO2005063232A1 Obesity and metabolic syndrome treatment with tanshinone derivatives which increase metabolic activity
07/14/2005WO2005063231A2 Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or esther thereof
07/14/2005WO2005063230A1 Use of conjugated linolenic acids for reducing body fat mass
07/14/2005WO2005063229A1 Pregabalin composition
07/14/2005WO2005063228A1 Glucose tolerance-improving agent
07/14/2005WO2005063227A1 Process for producing triterpene composition
07/14/2005WO2005063226A1 Compositions and methods for treating diabetes
07/14/2005WO2005063225A1 Compositions and methods for treating hepatitis c virus (hcv) infection
07/14/2005WO2005063224A1 Topical preparations containing dimethyl sulfoxide and dexpanthenol
07/14/2005WO2005063223A1 Zeaxanthin formulations with additional ocular-active nutriente, for protecting eye health and treating eye disorders
07/14/2005WO2005063221A1 Measuring vasodilating activity of blood samples to track disease course
07/14/2005WO2005063220A1 Modulation of 5-ht2 receptors as a treatment for cardiovascular diseases
07/14/2005WO2005063219A2 Ibuprofen-containing soft gelatin capsules
07/14/2005WO2005063218A2 Pharmaceutical formulations of bisphosphonates
07/14/2005WO2005063215A1 Anti-inflammatory analgesic external preparation
07/14/2005WO2005063214A1 Method for the production of an administration form which is secured against misuse
07/14/2005WO2005063211A2 Method of producing lipid complexed camptothecin-carboxylate
07/14/2005WO2005063210A2 Loading of a camptothecin drug into colloidal nanoparticles
07/14/2005WO2005063209A1 Self-microemulsifying drug delivery systems of a hiv protease inhibitor
07/14/2005WO2005063207A1 Nonaqueous gel preparation for external use
07/14/2005WO2005063206A1 Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
07/14/2005WO2005063199A1 Effervescent preparation of a basic medicinal substance
07/14/2005WO2005063195A2 Compositions comprising vitamins and/or derivatives thereof stabilised with olea europea extract and/or ionene polymers
07/14/2005WO2005063169A2 Medical lipolysis of fat accumulations
07/14/2005WO2005063147A1 Use of alginate matrices to control cell growth
07/14/2005WO2005063050A1 Method of increasing lean body mass and reducing body fat mass in infants
07/14/2005WO2005063010A1 A novel use of neuroactive compounds
07/14/2005WO2005062992A2 Substituted melatonin derivatives, process for their preparation, and methods of use
07/14/2005WO2005062991A2 Ten and 20-di-esterification derivatives of camptothecins and methods to treat cancers
07/14/2005WO2005062985A2 Di-ester prodrugs of camptothecin, process for their preparation and their therapeutical applications
07/14/2005WO2005062979A2 Immunoassays, haptens, immunogens and antibodies for anti-hiv therapeutics
07/14/2005WO2005062954A2 Modulation of hcn channels by second messengers
07/14/2005WO2005062913A2 Triplide 5,6-derivatives as immunomodulators and anticancer agents
07/14/2005WO2005062898A2 Enhanced absorption of modified release dosage forms
07/14/2005WO2005062897A2 Polymorphs of ezetimibe and processes for the preparation thereof
07/14/2005WO2005062894A2 Co-administration of dopamine-receptor binding compounds
07/14/2005WO2005062882A2 Rifamycin analogs and uses thereof
1 ... 4613 4614 4615 4616 4617 4618 4619 4620 4621 4622 4623 4624 4625 4626 4627 4628 4629 4630 4631 4632 4633 ... 7860